Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takeshi Sakamoto has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive Preclinical Pharmacokinetic Characterization of FAD012, a Rationally Designed Ferulic Acid Derivative, Supports Its Further Development as a Cerebrovascular Protective Therapeutic Candidate for Ischemic Stroke

    by Toshiya Aoyama, Satoshi Kitaoka, Hirokazu Matsuzaki, Jun Takayama, Bo Yuan, Meiyan Xuan, Takeshi Sakamoto, Yuya Egawa, Mari Okazaki

    Background/Objectives: FAD012 (3,5-dimethyl-4-hydroxycinnamic acid), a ferulic acid (FA) derivative, exhibits greater cerebroprotective effects than FA in experimental cerebral ischemia. Prophylactic oral administration of FAD012 preserves cerebral blood flow and blood–brain barrier integrity, consistent with its protective effects on the cerebrovascular endothelium. Compared with FA, FAD012 has higher calculated lipophilicity and a lower topological polar surface area, suggesting altered membrane permeability and systemic disposition. However, its pharmacokinetic characteristics remain unclear. Methods: This study compared the pharmacokinetics and tissue distribution of FAD012 and FA in male Sprague–Dawley rats. After intravenous and oral administration (10 mg/kg), plasma concentration–time profiles were analyzed using compartmental pharmacokinetic models. Tissue distribution after 2 weeks of dietary administration and plasma protein binding were also evaluated. Results: After intravenous administration, FAD012 exhibited a longer elimination half-life and tended to have a larger volume of distribution than FA, without a significant difference in total clearance. After oral administration, FAD012 showed more rapid absorption, with a higher maximum plasma concentration and a shorter time to maximum plasma concentration, with no significant differences in the area under the concentration–time curve or absolute bioavailability. After chronic administration, unchanged FAD012 was present at a higher plasma concentration, alongside lower tissue-to-plasma concentration ratios. FAD012 also exhibited markedly higher plasma protein binding than FA. Conclusions: These findings demonstrate that structural modification of FA to FAD012 alters absorption and systemic disposition without increasing absolute bioavailability. The higher plasma concentration of unchanged FAD012 observed after chronic administration may contribute to its cerebrovascular protective effects and support its potential as a prophylactically administered cerebroprotective agent for ischemic stroke.

  • A ferulic acid derivative FAD012 protects brain microvascular endothelial cells from H2O2-induced ferroptosis via NRF2 activation

    by Toshiya Aoyama, Meiyan Xuan, Satoshi Kitaoka, Jun Takayama, Bo Yuan, Hirokazu Matsuzaki, Yuya Egawa, Takeshi Sakamoto, Mari Okazaki


  • Open Access

    Design and Synthesis of Ferulic Acid Derivatives with Enhanced Antioxidant and Neuroprotective Activities: Discovery of Dual Antioxidant Agent

    by Koichi Shikama, Jun Takayama, Meiyan Xuan, Hirokazu Matsuzaki, Bo Yuan, Hiroyuki Teramae, Mari Okazaki, Takeshi Sakamoto

    Ferulic acid (FA) is well known for its antioxidant properties and neuroprotective effects. To enhance these biological activities, we designed a novel series of FA derivatives by introducing a phenyl group at the α-position of the carboxyl moiety. Further structural modifications were achieved by incorporating hydroxy or alkoxy substituents at various positions on the two aromatic rings. A series of these derivatives were synthesized and evaluated for their antioxidant capacity using the DPPH radical scavenging assay, as well as their cytoprotective effects against oxidative stress in Neuro-2a cells. Among the synthesized compounds, one derivative exhibited significantly enhanced activity in both assays. Mechanistic studies indicated that this heightened efficacy is attributable to a unique reaction pathway involving dual antioxidant mechanisms.


  • Open Access

    FAD012, a Ferulic Acid Derivative, Preserves Cerebral Blood Flow and Blood–Brain Barrier Integrity in the Rat Photothrombotic Stroke Model

    by Hiroshi Sugoh, Hirokazu Matsuzaki, Jun Takayama, Naohiro Iwata, Meiyan Xuan, Bo Yuan, Takeshi Sakamoto, Mari Okazaki

    Background/Objectives: The rapid progression of stroke often results in irreversible brain damage and poor outcomes when treatment is delayed. Prophylactic administration of FAD012 (3,5-dimethyl-4-hydroxycinnamic acid), a synthetic derivative of ferulic acid (FA), has demonstrated cerebroprotective effects in ischemic models through antioxidant and endothelial protective mechanisms. This study investigated the effects of FAD012 on cerebral infarction and blood–brain barrier (BBB) integrity using a photothrombotic stroke model in rats. Methods: Male Sprague Dawley rats received a single intraperitoneal injection of FAD012 or FA (100 or 300 mg/kg) 60 min prior to stroke induction. Under isoflurane anesthesia, the middle cerebral artery was exposed, and stroke was induced by intravenous administration of Rose Bengal followed by green laser irradiation. Cerebral blood flow (CBF) was monitored by laser Doppler flowmetry. BBB disruption was evaluated by Evans Blue extravasation and immunohistochemistry for tight junction (TJ) proteins. Results: Control rats exhibited extensive infarction, BBB disruption, and reduced expression of claudin-5, occludin, and ZO-1, along with fragmented collagen IV. In contrast, FAD012 (300 mg/kg) significantly attenuated CBF reduction, reduced infarct size, preserved BBB integrity, and maintained TJ protein expression, with greater efficacy than an equivalent dose of FA. FAD012 also preserved the expression and phosphorylation of endothelial nitric oxide synthase (eNOS), a key marker of vascular integrity. The CBF-preserving effect of FAD012 was completely abolished by NG-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor. Conclusions: These findings suggest that FAD012 protects endothelial function, thereby contributing to the maintenance of CBF and BBB integrity, supporting its potential as a prophylactic therapeutic agent for ischemic stroke.


  • Open Access

    CUD003, a Novel Curcumin Derivative, Ameliorates LPS-Induced Impairment of Endothelium-Dependent Relaxation and Vascular Inflammation in Mice

    by Hirokazu Matsuzaki, Anna Arai, Meiyan Xuan, Bo Yuan, Jun Takayama, Takeshi Sakamoto, Mari Okazaki

    Endothelial dysfunction is closely linked to inflammation and oxidative stress and ultimately contributes to the development of cardiovascular diseases. Lipopolysaccharide (LPS), a major component of Gram-negative bacteria, induces vascular inflammation and oxidative damage in experimental models. Curcumin (Cur), a polyphenol from Curcuma longa, is well known for its anti-inflammatory and antioxidant properties. In this study, we examined the protective effects of CUD003, a novel synthetic Cur derivative, on the LPS-induced impairment of endothelium-dependent relaxation in the thoracic aorta of mice. Male ICR mice were pretreated with CUD003 or Cur (3 or 10 mg/kg, p.o.) 30 min prior to LPS injection (10 mg/kg, i.p.). Twenty-four hours after LPS injection, vascular reactivity was assessed in isolated aortic rings by evaluating vasorelaxation and vasoconstriction responses. LPS markedly impaired acetylcholine-induced vasorelaxation in the phenylephrine (PE)-precontracted aortic rings, while PE-induced contraction and sodium nitroprusside-induced relaxation were preserved, indicating that LPS impaired endothelium-dependent relaxation without affecting smooth muscle function. Immunohistochemical analysis revealed a reduction in eNOS expression and elevated levels of TNF-α, COX-2, O2−, and malondialdehyde, indicating enhanced inflammation and oxidative stress in the aorta. Pretreatment with CUD003 (10 mg/kg) significantly ameliorated these changes and showed superior protective effects compared to the same dose of Cur. These findings suggest that CUD003 protects against LPS-induced vascular dysfunction and suppresses inflammation and oxidative stress, supporting its potential as a preventive candidate against vascular inflammation and dysfunction.


  • Open Access

    Chronic Administration with FAD012 (3,5-Dimethyl-4-hydroxycinnamic Acid) Maintains Cerebral Blood Flow and Ameliorates Swallowing Dysfunction After Chronic Cerebral Hypoperfusion in Rats

    by Takashi Asano, Hirokazu Matsuzaki, Meiyan Xuan, Bo Yuan, Jun Takayama, Takeshi Sakamoto, Mari Okazaki

    Dysphagia is a serious complication of stroke, yet effective pharmacological treatments remain limited. This study investigated the effects of FAD012 (3,5-dimethyl-4-hydroxy cinnamic acid), a synthetic derivative of ferulic acid (FA), on cerebral damage and swallowing dysfunction in a rat model of bilateral common carotid artery occlusion (2VO). Sprague–Dawley rats were orally administered FAD012 (3 or 10 mg/kg), FA (10 mg/kg), or 0.5% carboxymethyl cellulose (CMC, suspension vehicle) starting one week before 2VO. Two weeks after 2VO surgery, which was performed under isoflurane anesthesia, reflex swallowing was assessed by electromyographic recordings of the mylohyoid muscle under urethane anesthesia. Two weeks after 2VO, cerebral blood flow (CBF) declined to approximately 40% of baseline, and the number of reflex swallowing responses was significantly reduced in the CMC group. Additionally, 2VO induced O2− production, apoptotic cell death in the striatum, and a reduction in tyrosine hydroxylase expression. Substance P (SP) levels in the laryngopharyngeal mucosa, positively regulated by dopaminergic signaling in the basal ganglia, also decreased. FAD012 (10 mg/kg) effectively prevented the 2VO-induced reduction in CBF, enhanced the reflex swallowing, and preserved the dopamine-SP system. Notably, FAD012 exerted significantly stronger effects than FA at the same dose. These findings suggest that FAD012 maintains CBF under cerebral hypoperfusion and enhances the swallowing reflex by maintaining neuronal function in the striatal and laryngopharyngeal regions of 2VO rats.


  • Open Access

    Involvement of the Restoration of Cerebral Blood Flow and Maintenance of eNOS Expression in the Prophylactic Protective Effect of the Novel Ferulic Acid Derivative FAD012 against Ischemia/Reperfusion Injuries in Rats

    by Takashi Asano, Meiyan Xuan, Naohiro Iwata, Jun Takayama, Kousuke Hayashi, Yosuke Kato, Toshiya Aoyama, Hiroshi Sugo, Hirokazu Matsuzaki, Bo Yuan, et al.

    Tissue plasminogen activator, aiming to restore cerebral blood flow (CBF), has been used for acute ischemic strokes in clinics; however, its narrow therapeutic time window remains a serious concern. To develop novel prophylactic drugs to alleviate cerebral ischemia/reperfusion injuries, ferulic acid derivative 012 (FAD012) was synthesized and showed comparable antioxidant properties to ferulic acid (FA) and probably possesses the potent ability to cross the blood–brain barrier. A more potent cytoprotective effect of FAD012 against H2O2-induced cytotoxicity in PC12 cells was also observed. In vivo toxicity was not observed in rats given a long-term oral administration of FAD012, indicating its good tolerability. A one-week-course oral administration of FAD012 significantly alleviated middle cerebral artery occlusion (MCAO)-induced cerebral ischemia/reperfusion injuries in rats, accompanied by the restoration of CBF and endothelial nitrogen oxide synthetase (eNOS) expression. Treatment with FAD012 significantly restored the cell viability and eNOS expression damaged by H2O2, used to mimic MCAO-triggered oxidative stress, in rat brain microvascular endothelial cells. Our findings suggested that FAD012 protected the viability of vascular endothelium and maintained eNOS expression, ultimately contributing to the restoration of CBF, and may provide a rationale for the development of FAD012 into an effective prophylactic drug for patients at high risk of stroke.


  • Open Access

    Enhanced Cytotoxic Effects of Arenite in Combination with Active Bufadienolide Compounds against Human Glioblastoma Cell Line U-87

    by Bo Yuan, Jingmei Li, Shin-Ich Miyashita, Hidetomo Kikuchi, Meiyan Xuan, Hirokazu Matsuzaki, Naohiro Iwata, Shinya Kamiuchi, Katsuyoshi Sunaga, Takeshi Sakamoto, et al.

    The cytotoxicity of a trivalent arsenic derivative (arsenite, AsIII) combined with arenobufagin or gamabufotalin was evaluated in human U-87 glioblastoma cells. Synergistic cytotoxicity with upregulated intracellular arsenic levels was observed, when treated with AsIII combined with arenobufagin instead of gamabufotalin. Apoptosis and the activation of caspase-9/-8/-3 were induced by AsIII and further strengthened by arenobufagin. The magnitude of increase in the activities of caspase-9/-3 was much greater than that of caspase-8, suggesting that the intrinsic pathway played a much more important role in the apoptosis. An increase in the number of necrotic cells, enhanced LDH leakage, and intensified G2/M phase arrest were observed. A remarkable increase in the expression level of γH2AX, a DNA damage marker, was induced by AsIII+arenobufagin. Concomitantly, the activation of autophagy was observed, suggesting that autophagic cell death associated with DNA damage was partially attributed to the cytotoxicity of AsIII+arenobufagin. Suppression of Notch signaling was confirmed in the combined regimen-treated cells, suggesting that inactivation of Jagged1/Notch signaling would probably contribute to the synergistic cytotoxic effect of AsIII+arenobufagin. Given that both AsIII and arenobufagin are capable of penetrating into the blood–brain barrier, our findings may provide fundamental insight into the clinical application of the combined regimen for glioblastoma.


  • Open Access

    Protective Effects of Ferulic Acid against Chronic Cerebral Hypoperfusion-Induced Swallowing Dysfunction in Rats

    by Takashi Asano, Hirokazu Matsuzaki, Naohiro Iwata, Meiyan Xuan, Shinya Kamiuchi, Yasuhide Hibino, Takeshi Sakamoto, Mari Okazaki

    Ferulic acid (FA), a phenolic phytochemical, has been reported to exert antioxidative and neuroprotective effects. In this study, we investigated the protective effects of FA against the dysfunction of the swallowing reflex induced by ligation of bilateral common carotid arteries (2VO) in rats. In 2VO rats, topical administration of water or citric acid to the pharyngolaryngeal region evoked a diminished number of swallowing events with prolonged latency compared to sham-operated control rats. 2VO rats had an increased level of superoxide anion radical, and decreased dopamine and tyrosine hydroxylase enzyme levels in the striatum, suggesting that 2VO augmented cerebral oxidative stress and impaired the striatal dopaminergic system. Furthermore, substance P (SP) expression in the laryngopharyngeal mucosa, which is believed to be positively regulated by dopaminergic signaling in the basal ganglia, was decreased in 2VO rats. Oral treatment with FA (30 mg/kg) for 3 weeks (from one week before 2VO to two weeks after) improved the swallowing reflex and maintained levels of striatal dopamine and laryngopharyngeal SP expression in 2VO rats. These results suggest that FA maintains the swallowing reflex by protecting the dopamine-SP system against ischemia-induced oxidative damage in 2VO rats.


  • Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy

    by Ayako Hoshi, Takeshi Sakamoto, Jun Takayama, Meiyan Xuan, Mari Okazaki, Tracy L. Hartman, Robert W. Buckheit, Christophe Pannecouque, Mark Cushman